Navigate to
-
Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...
Prime Article: Research & Publications PA Research & Publications: FDA Decisions Expected -
This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.
Prime Article: Research & Publications PA Research & Publications: Drug Approvals -
This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.
Prime Article: Research & Publications PA Research & Publications: Drug Approvals -
Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime...
Prime Article: Research & Publications PA Research & Publications: Drug Approvals -
Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics
Prime Article: Events -
Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...
Prime Article: Research & Publications PA Research & Publications: FDA Decisions Expected -
Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes
Prime Article: Perspectives -
References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....